Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.

Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, Shinohara N.

Jpn J Clin Oncol. 2010 Oct;40(10):967-72. doi: 10.1093/jjco/hyq081. Epub 2010 Jun 3.

PMID:
20522448
2.

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.

J Urol. 2007 Dec;178(6):2372-6; discussion 2377. Epub 2007 Oct 22.

PMID:
17936834
3.

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group.

J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.

PMID:
18801505
4.

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W; North Central Cancer Treatment Group.

Urology. 2007 Feb;69(2):289-94.

PMID:
17320666
5.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.

PMID:
18801509
6.

Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.

Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1689-96.

7.
8.

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH.

Clin Cancer Res. 2005 Mar 1;11(5):1854-62.

9.

[A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].

Kawa G, Hiura Y, Satoh H, Sugi M, Fujita I, Oguchi N, Doi H, Ashida M, Okada H, Muguruma K, Murota T, Koyama Y, Kawamura H, Ohara T, Kawakita M, Matsuda T.

Hinyokika Kiyo. 2002 Mar;48(3):133-8. Japanese.

11.

Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.

Ansari MS, Gupta NP.

Urol Oncol. 2004 Sep-Oct;22(5):415-20.

PMID:
15464923
12.
13.

Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?

Schröder FH, Kranse R, Barbet N, Hop WC, Kandra A, Lassus M.

Prostate. 2000 Feb 1;42(2):107-15.

PMID:
10617867
14.

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.

Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.

J Urol. 2001 Dec;166(6):2198-201.

PMID:
11696735
15.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
16.

Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.

Schröder FH, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A.

Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1. Epub 2005 Oct 17.

PMID:
16263208
17.

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.

deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B.

Urology. 2004 Feb;63(2):259-63.

PMID:
14972467
18.

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.

Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.

J Urol. 2002 Aug;168(2):542-5.

PMID:
12131305
19.

Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.

Stege R, Grande M, Carlström K, Tribukait B, Pousette A.

Clin Cancer Res. 2000 Jan;6(1):160-5.

20.

The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992.

Schneider SB, Schweitzer VG, Parker RG, Bycott PW.

Am J Clin Oncol. 1996 Feb;19(1):65-72.

PMID:
8554039

Supplemental Content

Support Center